Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fritz Offner

Showing results (41-50 of 126) with videos related to

Pageof 13
Sort By:
Pharmacological Research|March 25, 2025
CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapyBert Luyckx, Maaike Van Trimpont, Fien Declerck, et al.
Cellular and Molecular Life Sciences : CMLS|August 14, 2023
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cellsDorien Clarisse, Stefan Prekovic, Philip Vlummens, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 27, 2006
In vitro screening for synergism of high-linear energy transfer 213Bi-radiotherapy with other therapeutic agents for the treatment of B-cell chronic lymphocytic leukemiaKatia Vandenbulcke, Hubert Thierens, Filip De Vos, et al.
Blood|November 18, 2010
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myelomaIoanna Papandreou, Nicholas C Denko, Michael Olson, et al.
Frontiers in Cell and Developmental Biology|June 27, 2022
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment ApproachPhilip Vlummens, Stefaan Verhulst, Kim De Veirman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphomaGeorg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
The Lancet. Oncology|September 18, 2015
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 studyMarinus H J van Oers, Kazimierz Kuliczkowski, Lukáš Smolej, et al.
Experimental Hematology & Oncology|June 3, 2024
High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphomaWillem Daneels, Alexander Van Parys, Leander Huyghe, et al.
British Journal of Haematology|April 3, 2020
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trialFritz Offner, Tadeusz Robak, Ann Janssens, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Pageof 13

Showing results (41-50 of 126) with videos related to

Sort By:
Pageof 13
Pharmacological Research|March 25, 2025
CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapyBert Luyckx, Maaike Van Trimpont, Fien Declerck, et al.
Cellular and Molecular Life Sciences : CMLS|August 14, 2023
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cellsDorien Clarisse, Stefan Prekovic, Philip Vlummens, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 27, 2006
In vitro screening for synergism of high-linear energy transfer 213Bi-radiotherapy with other therapeutic agents for the treatment of B-cell chronic lymphocytic leukemiaKatia Vandenbulcke, Hubert Thierens, Filip De Vos, et al.
Blood|November 18, 2010
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myelomaIoanna Papandreou, Nicholas C Denko, Michael Olson, et al.
Frontiers in Cell and Developmental Biology|June 27, 2022
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment ApproachPhilip Vlummens, Stefaan Verhulst, Kim De Veirman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphomaGeorg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
The Lancet. Oncology|September 18, 2015
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 studyMarinus H J van Oers, Kazimierz Kuliczkowski, Lukáš Smolej, et al.
Experimental Hematology & Oncology|June 3, 2024
High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphomaWillem Daneels, Alexander Van Parys, Leander Huyghe, et al.
British Journal of Haematology|April 3, 2020
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trialFritz Offner, Tadeusz Robak, Ann Janssens, et al.
British Journal of Haematology|November 19, 2014
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasoneGareth Morgan, Antonio Palumbo, Sujith Dhanasiri, et al.
Pageof 13